HBOT Conversations:
Dr. Paul Harch & Autism

Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.

He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.

This episode on Autism is the seventh in a nine episode series that will be released weekly with Dr. Harch.

Subscribe. Join the discussion. Share the hope.

Watch the Podcast

In episode 7 of 9, host Edward di Girolamo speaks with world renowned HBOT expert, Dr. Paul G. Harch about Autism.

The percentage of children with Autism is increasing at an alarming rate. In order to successfully treat Autism and navigate around the roadblocks, Dr. Harch explains that it’s important to understand that Autism is not a psychiatric diagnosis. Autism is a wounding condition of the brain, without all of the potential contributors being identified to the wounding process.

Dr. Harch was the first to treat a series of children with Autism using Hyperbaric Oxygen Therapy; a therapy which in and of itself is neuroplastic (it is a neuroplast — affecting neuroplasticity). He states that there’s a plethora of information on the fact that Autism is a physical brain abnormality, and that’s what’s causing this Autism phenomenon. Functional imaging scans that have been done on these Autistic children shows 90% of them have a problem involving primarily the temporal lobes and frontal lobes; mostly temporal lobes. Dr. Harch has treated a good series of these children with Hyperbaric Oxygen Therapy and about 80% of them will respond to the treatment. There are various causes, which may explain why 100% don’t respond to HBOT, since there are different insults to the brains and/or it’s environmental. But, Dr. Harch stresses that there’s no such thing as a genetic epidemic, so this Autism epidemic we’re seeing must either be caused by environmental factors or infectious agents.

Dr. Harch affirms that the underlying nature of Autism is that there’s a dominant immune dysfunction in these children that often manifests in the GI tract, but also in the brain. Dr. Harch recommends our viewers read this beautiful article by Dr. Dan Rossignol, a Family Practice Physician with two autistic sons. In the article Dr. Rossignol reviews all of the pathophysiology — the disease processes — that have been identified in Autistic children, and he reviews all of the science of Hyperbaric Oxygen Therapy and the effect it has on all of those disease processes. In the end, HBOT is shown to be a good match for the treatment of Autism.

di Girolamo asks Dr. Harch if Autism appears to be an inflammatory issue, with Dr. Harch agreeing that it does seem to appear that way. Dr. Harch went on to explain that of the 8,1001 genes that have been shown to be affected in human cells by a single Hyperbaric Oxygen exposure, the largest clusters involved are the anti-inflammatory genes — upregulation is turned on and there’s suppression of the pro-inflammatory genes.  Plus, there are many genes that are activated within the immune system which also supports the use of HBOT for the treatment of Autism as a dominant immune dysfunction.

The studies have been controversial and complicated on Hyperbaric Oxygen Therapy for Autism. But contrary to the results of these studies, Dr. Harch is here to say that the proof is in the imaging.  He has imaging revealing that after only one treatment — sometimes it’s a series of treatments — changes are seen in these children’s brains, and there’s improvement in profusion (such as in the temporal lobes).

Dr. Harch professes that what he’s been trying to do all these years, these decades, is to answer a simple question, “Does Hyperbaric Oxygen Therapy work for your condition or not?” He explains it’s critical to start with HBOT solely and not throw a bunch of other therapies into the mix because then you have too many variables, and you won’t know exactly what’s helping and what’s not.  He explains Hyperbaric Oxygen Therapy is a foundation biological therapy, and declares there is no identified therapy out there that can do what Hyperbaric Oxygen can do; including activating 40% of our genome. There’s nothing.

Dr. Harch references Chapter 12 of his book, The Oxygen Revolution, and says “I’m sorry but if your doctor is giving you negative information, flatly ignore him! Go get this therapy for your child!” Treating with HBOT is no different than if you dosed the child with a drug, or a drug combination. This is a two component drug we’re dosing with that’s safe and effective — pressure and oxygen.  We encourage you to try it, because it could change your life if you or your child are a part of this 80% success rate.

 

Subscribe Now, It’s Free!

[contact-form-7 id="65934" title="Subscribe"]

Guest

Dr. Paul G. Harch

Dr. Paul G. Harch, MD

Dr. Paul G. Harch, M.D. is a clinician in emergency medicine and hyperbaric medicine who is the former director of the University Medical Center Hyperbaric Medicine Department and LSU Hyperbaric Medicine Fellowship. Currently, he is a Clinical Professor of Medicine in the Section of Emergency Medicine at LSU School of Medicine in New Orleans. He graduated from the Johns Hopkins University School of Medicine after graduating from the University of California at Irvine with magna cum laude/Phi Beta Kappa honors.

Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.

Harch HBOT – Hyperbaric Oxygen Therapy Clinic

5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/

 

Recent HBOT News

Clinical Trial – the Use of Magnesium Sulfate for Prevention of Postspinal Shivering

Shivering is an unpleasant experience after spinal anesthesia. Shivering is defined as an
involuntary, repetitive activity of skeletal muscles. The mechanisms of shivering in patients
undergoing surgery are mainly intraoperative heat loss, increased sympathetic tone, pain, and
systemic release of pyrogens. Spinal anesthesia significantly impairs the thermoregulation
system by inhibiting tonic vasoconstriction, which plays a significant role in temperature
regulation. Spinal anesthesia also causes redistribution of core heat from the trunk (below
the block level) to the peripheral tissues. These two effects predispose patients to
hypothermia and shivering. The median incidence of shivering related to regional anesthesia
observed in a review of 21 studies is 55%. Shivering increases oxygen consumption, lactic
acidosis, carbon dioxide production, and metabolic rate by up to 400%. Therefore, shivering
may cause problems in patients with low cardiac and pulmonary reserves. The best way to avoid
these intraoperative and postoperative shivering-induced increases in hemodynamic and
metabolic demands is to prevent shivering in the first place. Although magnesium is among
several pharmacological agents used for the treatment of shivering, its effects on prevention
of shivering during central neuraxial blockade have not been evaluated to date. Henceforth,
the aim of this study was to evaluate the effect of magnesiume on shivering during spinal
anesthesia.

Aim:

to compare the efficacy of intravenous versus intrathecal magnesium sulphate for prevention
of post spinal shivering in adult patients undergoing elective lower limb orthopedic
surgeries.

Clinical Trial – Comparing the Effects of Levobupivacaine and Bupivacaine in Saddle Spinal Anesthesia

İn this study; it was aimed to investigate the effects of equipotent doses of hyperbaric
bupivacaine and hyperbaric levobupivacaine in outpatient anorectal surgery under saddle
block. Sixty patients between the age of 18- 50 and in the risk group of ASA I-II included in
the study. 7,5 mg of 0,5% hyperbaric bupivacaine or 7,5 mg of 0,5% hyperbaric levobupivacaine
injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral
space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after
intrathecal injection and than layed in supine position, finally they positioned in prone
jack-knife. Hemodynamic parameters like NIBP, HR, SpO2, sensory and motor block
characteristics, duration of analgesia, time of first voiding, mobilization time, patient and
surgeon satisfaction, adverse effects and discharge time were recorded during and after
surgery.